CDK4 and soft tissue sarcoma: Amplification of CDK4 and its cyclin partner CCND1, as well as the deletion of CDKN2A (an inhibitor of CDK4/6), is associated with worse survival in patients with advanced soft tissue sarcomas (Figure 2) [44,45].